Fredrik Piehl Honored as Årets Neuroprofil 2025 for Contributions to Neurology

Fredrik Piehl, professor of neurology at the Karolinska Institutet, has been awarded the Årets Neuroprofil 2025 title by Neuroförbundet, recognizing his significant contributions to the field of neurology. The accolade was determined through a vote by Neuroförbundet's members on social media, celebrating accomplishments that enhance the care of individuals with neurological conditions.

Piehl's research, particularly focused on inflammatory diseases of the central and peripheral nervous systems, has gained notable attention. His team has conducted groundbreaking studies on the efficacy and safety of rituximab as a treatment for multiple sclerosis (MS), demonstrating promising results that highlight a beneficial risk-to-reward ratio. Beyond MS, his research also encompasses areas such as myasthenia gravis, psychiatric disorders, and traumatic brain injuries.

Notably, Piehl balances his role in research with patient care and educational efforts, frequently lecturing on neurology. He has been active in the Neuroförbundet's research committee and manages the quality register for myasthenia gravis through the Swedish Neuroregister, further contributing to advancements in neurological care in Sweden.

Upon receiving this distinguished award, Piehl expressed gratitude and dedication, stating, "My primary goal with research is to improve care and address issues that are important for our patients. I see this award as a confirmation that we are on the right track." This acknowledgment underscores the impactful work Piehl continues to pursue in neurology.